文献速递心脑血管急症重症综合管理与镇静镇痛

可溶性CD59对心肺复苏后患者28天神经预后不良和全因死亡的预测价值:一项前瞻性观察性研究

Predictive value of soluble CD59 for poor 28-day neurological prognosis and all-cause mortality in patients after cardiopulmonary resuscitation: a prospective observatory study.
PubMed 文献 · J Intensive Care · 2023-02-02
一句话结论心脏骤停ROSC后血清sCD59升高,第3天预测28天神经预后不良AUC 0.862、全因死亡AUC 0.891,第1天sCD59为独立相关因素。

该前瞻性观察性研究纳入68例ROSC后患者(存活组23例、非存活组45例)和20名健康志愿者,于ROSC后第1、3、7天检测血清sCD59及其他补体成分、炎症介质和神经损伤标志物。结果显示ROSC后患者上述指标普遍升高,非存活组高于存活组(C1q和MBL除外);sCD59与sC5b-9、TNF-α、IL-6、NSE、S100β、SOFA评分和APACHE II评分正相关。第3天sCD59预测28天神经预后不良的AUC为0.862(95%CI 0.678-0.960),预测28天全因死亡的AUC为0.891(95%CI 0.769-0.962);多因素logistic回归显示第1天sCD59水平与两者独立相关。提示sCD59可能作为ROSC后病情严重程度和预后的血清标志物。

要点

  • ROSC后第1、3、7天血清sCD59均升高,非存活组高于存活组,且与SOFA评分、APACHE II评分正相关。
  • 第3天sCD59预测28天神经预后不良(CPC 3-5分)的AUC为0.862(95%CI 0.678-0.960)。
  • 第3天sCD59预测28天全因死亡的AUC为0.891(95%CI 0.769-0.962)。
  • 多因素logistic回归显示第1天sCD59水平与28天神经预后不良和全因死亡独立相关。
  • sCD59与sC5b-9、TNF-α、IL-6、NSE、S100β正相关,提示补体激活与炎症、神经损伤相关。

适用人群与场景

  • 心脏骤停后恢复自主循环(ROSC)的成人患者,共68例,按28天生存分为存活组23例和非存活组45例。
  • 对照为20名健康志愿者。

诊断标准与关键阈值

  • 神经预后采用大脑功能分类评分(cerebral performance category scores)评估,预后不良定义为3-5分。

研究设计与关键结果

  • 研究类型:前瞻性观察性研究;样本量:68例ROSC后患者和20名健康志愿者;人群:ROSC后患者。
  • ROSC后第1周,患者血清sCD59、sC5b-9、C5a、C3a、C3b、C1q、MBL、Bb、TNF-α、IL-6、NSE和S100β均较健康志愿者显著升高;除C1q和MBL外,非存活组上述指标较存活组显著升高。
  • 血清sCD59与sC5b-9、TNF-α、IL-6、NSE、S100β、SOFA评分和APACHE II评分呈正相关。
  • 第3天sCD59预测28天神经预后不良的AUC最高,为0.862(95%CI 0.678-0.960)。
  • 第3天sCD59预测28天全因死亡的AUC最高,为0.891(95%CI 0.769-0.962)。
  • 多因素logistic回归分析显示,第1天血清sCD59水平与28天神经预后不良和全因死亡独立相关。

证据类型、等级与局限

  • 证据类型:前瞻性观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,ROSC后血清sCD59升高与疾病严重程度正相关,且对28天神经预后不良和全因死亡有较好的预测价值。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: sCD59, as a soluble form of CD59, is observed in multiple types of body fluids and correlated with the cell damage after ischemia/reperfusion injury. This study aims to observe the dynamic changes of serum sCD59 in patients after restoration of spontaneous circulation (ROSC) and explore the association of serum sCD59 with neurological prognosis and all-cause mortality in patients after ROSC.

METHODS: A total of 68 patients after ROSC were prospectively recruited and divided into survivors (n = 23) and non-survivors (n = 45) groups on the basis of 28-day survival. Twenty healthy volunteers were enrolled as controls. Serum sCD59 and other serum complement components, including sC5b-9, C5a, C3a, C3b, C1q, MBL, Bb, and pro-inflammatory mediators tumor necrosis factor (TNF)-α, interleukin-6 (IL-6), neurological damage biomarkers neuron-specific enolase (NSE) and soluble protein 100β (S100β) were measured by enzyme linked immunosorbent assay on day 1, 3, and 7 after ROSC. Neurologic outcome was assessed using cerebral performance category scores, with poor neurologic outcome defined as 3-5 points.

RESULTS: In the first week after ROSC, serum levels of sCD59, sC5b-9, C5a, C3a, C3b, C1q, MBL, Bb, TNF-α, IL-6, NSE and S100β were significantly elevated in patients after ROSC compared to healthy volunteers, with a significant elevation in the non-survivors compared to survivors except serum C1q and MBL. Serum sCD59 levels were positively correlated with serum sC5b-9, TNF-α, IL-6, NSE, S100β, SOFA score and APACHE II score. Moreover, serum sCD59 on day 1, 3, and 7 after ROSC could be used for predicting poor 28-day neurological prognosis and all-cause mortality. Serum sCD59 on day 3 had highest AUCs for predicting poor 28-day neurological prognosis [0.862 (95% CI 0.678-0.960)] and 28-day all-cause mortality [0.891 (95% CI 0.769-0.962)]. In multivariate logistic regression analysis, the serum level of sCD59D1 was independently associated with poor 28-day neurological prognosis and all-cause mortality.

CONCLUSIONS: The elevated serum level of sCD59 was positively correlated with disease severity after ROSC. Moreover, serum sCD59 could have good predictive values for the poor 28-day neurological prognosis and all-cause mortality in patients after ROSC.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Wang L, Li RF, Guan XL, et al. Predictive value of soluble CD59 for poor 28-day neurological prognosis and all-cause mortality in patients after cardiopulmonary resuscitation: a prospective observatory study. J Intensive Care. 2023. PMID: 36732841. doi:10.1186/s40560-023-00653-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。